We have the state of the art Research and Development (R & D) facility — ‘Gennova Vaccine Formulation Centre and Research Laboratory’ which is recognized by Department of Scientific and Industrial Research (DSIR) with lab space of over 44,000 sq. ft.
The R & D facility was established with the following primary objectives:
- Recombinant cell line development for protein therapeutics and antigens as vaccine candidates;
- Process development for protein therapeutics and antigens as vaccine candidates;
- Product characterization and analytical method development; Formulation development.
The current PDL unit has molecular biology, upstream process development, downstream process development, analytical development and formulation development laboratories for making research and clinical grade for phase-1 biologics for therapeutic and vaccine purpose. Gennova have proven expertise in three expression platforms which includes mammalian cells, yeast cells and microbial expression technology. Gennova has the capability of designing and execution of processes from gene to finish products. Our formulation facility can produce GMP grade material for clinical trials up to phase-1. Gennova as a company focuses on optimizing processes that will eventually result in transforming the healthcare.
